A strong,inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 12, Issue 6, 1999, Pages 400-406

  Testa, Roberto ^a   Bonfigli, A R ^a   Sirolla, C ^a   Pieri, C ^a   Marra, M ^a   Antonicelli, R ^a   Manfrini, S ^b   Compagnucci, P ^b   Testa, I ^b  

^a INRCA   (Italy)

^b NONE

Author keywords

Diabetes mellitus; Hypertension; Lipoprotein(a); Plasminogen activator inhibitor Type 1

Indexed keywords

ANTIGEN; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FIBRINOLYSIS; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; VASCULAR DISEASE;

AGED; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; LIPOPROTEIN(A); MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIGLYCERIDES;

EID: 0033367093     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Wiman B., Hamsten A.: The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin. Thromb. Haemost. 16: 207-216, 1990.
2. Speiser W., Bowry S., Anders E., Binder B.R., Müller-Berghaus G.: Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-CAP) in plasma, platelets and endothelial cells. Thromb. Res. 44: 503-515, 1986.
3. Levin E.G.: Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 67: 1309-1313, 1986.
4. Sprengers E.D., Kluft C.: Plasminogen activator inhibitors. Blood 69: 381-387, 1987.
5. Loskutoff D.J.: Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy. Semin. Thromb. Haemost. 14: 100-109, 1988.
6. Krempler F., Kostner G., Bolzano K., Sandhofer F.: Lipoprotein(a) is not a metabolic product of other lipoproteins containing apolipoprotein B. Biochim. Biophys. Acta 575: 63-70, 1979.
7. Koschinsky L.M., Marcovina S.M.: Lipoprotein(a): structural implication for pathophysiology. Int. J. Clin. Lab. Res. 27: 14-23, 1997.
8. Harpel P.C., Gordon B.R., Parker T.S.: Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc. Natl. Acad. Sci. USA 86: 3847-3851, 1989.
9. Simon D.I., Fless G.M., Scanu A.M., Loscalzo J.: Tissue type plasminogen activator binds to ant is inhibited by surface-bound Lp(a) and LDL. Biochemistry 30: 6671-6677, 1991.
10. Fuller J.H., Keen H., Jarret R.J.: Hemostatic variables associated with diabetes and its complication. B.M.J. 2: 964-966, 1979.
11. Auwerx J., Bouillon R., Collen D., Geboers J.: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68-72, 1988.
12. Walmsley D., Hampton K.K., Grant P.J.: Contrasting fibrinolytic responses in type 1 (insulin dependent) and type 2 (non insulin dependent) diabetes. Diabet. Med. 8: 954-959, 1991.
13. Glueck C.J., Glueck H.I., Hamer T., Speirs J., Tracy T., Stroop D.: Beta-Blockers Lp(a), Hypertension, and reduced basal fibrinolytic activity. Am. J. Med. Sci. 307: 317-324, 1994.
14. Trifiletti A., Barbera M., Pizzoleo M.A., Lasco A., Lucifora S., Leone G., Soraci S., Pedulla M., Frisina M.: Haemostatic variables in arterial hypertension. Haemostasis 25: 237-240, 1995.
15. Asplund K., Olsson T., Viitanen N., Dahlén G.: Lp(a) lipoprotein in patients with acute stroke. Cerebrovascular Disease 1: 90-96, 1991.
16. Donders S.H.J., Lustermans F.A.T., Van Wersch J.W.J.: Coagulation factors and lipid composition of the blood in treated and untreated hypertensive patients. Scand. J. Clin. Lab. Invest. 53: 179-186, 1993.
17. Hancu N., Netea M.G., Iancu S.: Serum lipoprotein(a) is increased in hypertensive NIDDM patients. Diabetes Care 18: 879-880, 1995.
18. Kostner G.M., Krempler F.: Lipoprotein(a). Curr. Opin. Lipidol. 3: 279-284, 1992.
19. Morishita E., Asakura H., Jokaji H., Saito M., Uotani C., Kumabashiri L., Yamazaki M., Aoshima K., Hashimoto T., Matsuda T.: Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 120: 7-14, 1996.
20. Park Y.S., Park S., Kim S.Y., Lee H.K., Koh C.S., Min H.K., Kim J.Q.: The effect of obesity on fibrinolytic activity and plasma lipoprotein(a) levels in patients with type 2 diabetes mellitus in Korea. Diabetes Res. Clin. Pract. 24: 25-31, 1994.
21. Ho C.H., Jap T.S.: Relationship of plasminogen activator inhibitor-1 with plasma insulin, glucose, triglyceride and cholesterol in Chinese patients with diabetes. Thromb. Res. 69: 271-277, 1993.
22. Vukovich T., Schernthaner G.: The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic-patients. Thromb. Haemost. 68: 253-256, 1992.
23. Jokaji H., Asakura H., Saito M., Uotani C., Kumabashiri I., Morishita E., Yamazaki M., Matsuda T.: Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM). Nippon Ronen Igakkai Zasshi 27: 699-705, 1990.
24. Joven J., Vilella E.: Serum levels of lipoprotein(a) in patients with well controlled non insulin dependent diabetes mellitus. J.A.M.A. 265: 1113-1114, 1991.
25. Wall U., Jern C., Bergbrant A., Jern S.: Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 26: 796-800, 1995.
26. De Souza C.A., Dengel D.R., Rogers M.A., Cox K., Macko R.F.: The fibrinolytic system is not impaired in older men with hypertension. Hypertension 27: 1053-1058, 1996.
27. Flesch M., Sachinidis A., Ko Y.D., Kraft K., Vetter H.: Plasma lipids and lipoproteins and essential hypertension. Clin. Invest. 72: 944-950, 1994.
28. Rodriguez Reguero J.J., Iglesias Cubero G., Martinez Celada M., Fueyo J.R., Sanchez Posada I., Braga S., Cortina A.: Interrelationships between lipoprotein(a) and other cardiovascular risk factors. Cardiology 86: 432-435, 1995.
29. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L.: Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J. Biol. Chem. 266: 2459-2465,1991.
30. Terres W., Krewitt M., Hamm C.W.: Effects of Lipoprotein(a) on in vitro lysis on whole blood thrombi from healthy volunteers. Thromb. Res. 69: 479-487, 1993.
31. Heinrich J., Sandkamp M., Kokott R., Schulte H., Assmann G.: Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin. Chem. 37: 1950-1954, 1991.
32. Sundell I.B., Nilsson T.K., Hallmans G., Hellsten G., Dahlen G.H.: Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 80: 9-16, 1989.
33. Testa R., Bonfigli A.R., Piantanelli L., Manfrini S., Testa I., Gregorio F.: Relationship between plasminogen activator inhibitor type I plasma levels and the lipoprotein(a) concentrations in non insulin dependent diabetes mellitus. Diabetes Res. Clin. Pract. 33: 111-118, 1996.
34. Testa R., Bonfigli A.R., Pieri C., Marra M., Sirolla C., Manfrini S., Testa I.: A significant relationship between Plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus without complications. Int. J. Clin. Lab. Res. 28: 187-191, 1998.
35. Huisveld I.A., Leenen R., van der Kooy K., Hospers J.E.H., Seidell J.C., Deurenberg P., Koppeschaar H.P.F., Mosterd W.L., Bouma B.N.: Body composition and weight reduction in relation to antigen and activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 4: 84-85, 1990.
36. Oseroff A., Krishnamurti C., Hassett A., Tang D., Alving B.: Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J. Lab. Clin. Med. 113: 88-93, 1989.
37. Stief T.V.: Non radical excited oxygen species induce selective thrombolysis in vivo. Thromb. Res. 62: 147-163, 1991.
38. Ceriello A., Curcio F., dello Russo P., Pegoraro I., Stel G., Amstad P., Cerutti P.: The defense against free radicals protects endothelial cells from hyperglycaemia-induced plasminogen activator inhibitor 1 over-production. Blood Coagul. Fibrinolysis 6: 133-137, 1995.
39. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 25: 245-249, 1979.
40. Ligthart G.J., Corberand J.X., Fournier C., Galanaud P., Hijman W., Kennes B., Muller-Hermelink H.K., Steimann G.G.: Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech. Ageing Dev. 28: 47-55, 1984.
41. Declerk P.J.: Multicenter evaluation of commercially available methods for the immunological determination of plasminogen active or inhibitor-1 (PAI-1). Thromb. Haemost. 70: 858-863, 1993.
42. Juan-Vague I., Moerman B., De Cock F., Aillaud M.F., Collen D.: Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb. Res. 33: 523-530, 1984.
43. Masson C., Angles-Cano E.: Quantification de l'inhibiteur specifique (PAI-1) de l'activateur tissulaire du plasminogene (t-PA) dans le plasma. Ann. Biol. Clin. 47: 269-274, 1989.
44. Cao G., Alessio H.M., Cutler R.G.: Oxygen-radical absorbance capacity assay for antioxidants. Free Radic. Biol. Med. 14: 303-311, 1993.
45. Schreiner P.J., Heiss G., Tyroler H.A., Morrisett J.D., Davis C.E., Smith R.: Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler. Thromb. Vasc. Biol. 16: 471-478, 1996.
46. Martinez-Triguero M.L., Salvador A., Samper M.J., Almela M., Vega L., Mora A., Martinez-Diago V.: Lipoprotein(a) and other risk factors in patients with non-insulin-dependent diabetes mellitus. Coron. Artery Dis. 5: 755-760, 1994.
47. Gray R.P., Hydkin J.S., Patterson D.L.: Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br. Heart J. 69: 228-232, 1992.
48. Tipping P.G., Davenport P., Gallicchio M., Filonzi E.L., Apostolopoulos J., Wojta J.: Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothclial cells and vascular smooth muscle cells. Am. J. Pathol. 143: 875-885, 1993.
49. Jurgens G., Taddei-Peters W.C., Koltringer P., Petek W., Chen Q., Greilberger J., Macomber P.F., Butman B.T., Stead A.G., Ransom J.H.: Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 26: 1841-1848, 1995.
50. Takada Y., Urano T., Watanabe I., Taminato A., Yoshimi T., Takada A.: Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb. Res. 71: 405-415, 1993.